These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21586630)

  • 1. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.
    Zhou H; Marks JW; Hittelman WN; Yagita H; Cheung LH; Rosenblum MG; Winkles JA
    Mol Cancer Ther; 2011 Jul; 10(7):1276-88. PubMed ID: 21586630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.
    Zhou H; Ekmekcioglu S; Marks JW; Mohamedali KA; Asrani K; Phillips KK; Brown SA; Cheng E; Weiss MB; Hittelman WN; Tran NL; Yagita H; Winkles JA; Rosenblum MG
    J Invest Dermatol; 2013 Apr; 133(4):1052-62. PubMed ID: 23190886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
    Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
    Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.
    Zhou H; Mohamedali KA; Gonzalez-Angulo AM; Cao Y; Migliorini M; Cheung LH; LoBello J; Lei X; Qi Y; Hittelman WN; Winkles JA; Tran NL; Rosenblum MG
    Mol Cancer Ther; 2014 Nov; 13(11):2688-705. PubMed ID: 25239934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an Fn14 agonistic antibody as an anti-tumor agent.
    Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB
    MAbs; 2011; 3(4):362-75. PubMed ID: 21697654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.
    Dhruv H; Loftus JC; Narang P; Petit JL; Fameree M; Burton J; Tchegho G; Chow D; Yin H; Al-Abed Y; Berens ME; Tran NL; Meurice N
    J Biol Chem; 2013 Nov; 288(45):32261-32276. PubMed ID: 24056367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.
    Gu L; Dai L; Cao C; Zhu J; Ding C; Xu HB; Qiu L; Di W
    PLoS One; 2013; 8(3):e57436. PubMed ID: 23469193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.
    Aronin A; Amsili S; Prigozhina TB; Tzdaka K; Rachmilewitz J; Shani N; Tykocinski ML; Dranitzki Elhalel M
    PLoS One; 2013; 8(10):e77050. PubMed ID: 24130833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.
    Tran NL; McDonough WS; Savitch BA; Sawyer TF; Winkles JA; Berens ME
    J Biol Chem; 2005 Feb; 280(5):3483-92. PubMed ID: 15611130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
    Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
    Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
    Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL
    Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway.
    Michaelson JS; Burkly LC
    Results Probl Cell Differ; 2009; 49():145-60. PubMed ID: 19513634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).
    Fick A; Lang I; Schäfer V; Seher A; Trebing J; Weisenberger D; Wajant H
    J Biol Chem; 2012 Jan; 287(1):484-495. PubMed ID: 22081603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.
    Chopra M; Brandl A; Siegmund D; Mottok A; Schäfer V; Biehl M; Kraus S; Bäuerlein CA; Ritz M; Mattenheimer K; Schwinn S; Seher A; Grabinger T; Einsele H; Rosenwald A; Brunner T; Beilhack A; Wajant H
    Blood; 2015 Jul; 126(4):437-44. PubMed ID: 26012567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity.
    Zaitseva O; Hoffmann A; Löst M; Anany MA; Zhang T; Kucka K; Wiegering A; Otto C; Wajant H
    Front Immunol; 2023; 14():1194610. PubMed ID: 37545514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity.
    Willis AL; Tran NL; Chatigny JM; Charlton N; Vu H; Brown SA; Black MA; McDonough WS; Fortin SP; Niska JR; Winkles JA; Cunliffe HE
    Mol Cancer Res; 2008 May; 6(5):725-34. PubMed ID: 18505918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.
    Trebing J; Lang I; Chopra M; Salzmann S; Moshir M; Silence K; Riedel SS; Siegmund D; Beilhack A; Otto C; Wajant H
    MAbs; 2014; 6(1):297-308. PubMed ID: 24135629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.
    Perez JG; Tran NL; Rosenblum MG; Schneider CS; Connolly NP; Kim AJ; Woodworth GF; Winkles JA
    Oncogene; 2016 Apr; 35(17):2145-55. PubMed ID: 26300004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TWEAK/Fn14 signaling in tumors.
    Hu G; Zeng W; Xia Y
    Tumour Biol; 2017 Jun; 39(6):1010428317714624. PubMed ID: 28639899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.